Research shows that cannabinoids have medical application for a range of conditions as varied as epilepsy, glaucoma, osteoporosis, anorexia, Alzheimer’s disease and pain treatment.
Following the recent success of the CBD Medical Advisory Board meeting led by Inergetics’ Chief Science Officer, Carl Germano, RD, CNS, CDN, Inergetics has successfully procured targeted cannabinoids from industrial hemp, cannabis and other unique dietary sources.
"This is a critical milestone for us in our quest to enter the marketplace as the gold standard of cannabinoid supplements," says Germano. "Innovation in cannabinoid extraction from food sources other than cannabis and hemp as well as leading technology to enhance bioavailability was our number one goal in this important phase of the initiative and we achieved it."
"Our considerable momentum completing Phase I of our CBD product development is timely with growing validation in the marketplace as a major national news organization like The New York Times takes a position as it did this Sunday, July 27th in its editorial section calling for the national legalization of cannabis," said Inergetics CEO Mike James.
"In addition, it is important to note that the medical applications of cannabis and CBD are varied with the greatest opportunity in the broader consumer marketplace. Our progress is significant and puts Inergetics on the leading edge of this business."
Inergetics’ CBD-based supplements are expected to be distributed via medicinal marijuana dispensaries in 2015.